Side-by-side comparison of AI visibility scores, market position, and capabilities
Wearable blood pressure monitoring sticker with OR-grade accuracy; awaiting FDA clearance after 500+ patient clinical studies for hospital surgery and home cardiovascular monitoring.
Vena Vitals is a medical device company developing wearable continuous blood pressure monitoring technology — manufacturing adhesive sensor stickers that provide operating room-grade blood pressure accuracy using photoplethysmography (PPG) and proprietary algorithms, without the discomfort or interruption of traditional cuff-based blood pressure measurement. Founded in 2019 in Irvine, California, Vena Vitals has completed clinical studies on 500+ patients and is preparing its FDA submission for clearance to market the device for in-hospital (surgical and critical care) and home monitoring applications.\n\nVena Vitals' wearable patch applies to the wrist or finger and continuously monitors blood pressure beat-by-beat using optical sensors — providing the continuous monitoring currently limited to invasive arterial line catheters in ICUs or intermittent readings from arm cuffs. Continuous non-invasive blood pressure monitoring is clinically valuable during surgery (where blood pressure fluctuates significantly) and for patients with cardiovascular conditions or sleep disorders where blood pressure patterns during sleep and activity provide diagnostic insight. The device targets a significant cost reduction compared to invasive arterial line monitoring.\n\nIn 2025, Vena Vitals is in the regulatory submission phase, positioning for FDA clearance that would unlock commercial deployment in hospitals and the growing consumer remote patient monitoring market. The continuous non-invasive blood pressure market is competitive — Samsung (Galaxy Watch blood pressure), Apple (researching blood pressure for Apple Watch), Withings, and medical device companies including Omron and iHealth are pursuing cuffless blood pressure monitoring. However, most consumer wearable approaches have not achieved clinical-grade accuracy, which is Vena Vitals' key differentiator. FDA clearance would position Vena Vitals for partnerships with hospital systems and RPM (remote patient monitoring) program operators.
NYC YC "TurboTax for Medicaid" at $22M total ($18M a16z Series A Jul 2025) with AI + live navigators reducing member churn 15% addressing $50B administrative waste; 12-person team competing with Maximus for Medicaid enrollment technology.
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowitz (a16z) with BoxGroup, and a $4 million seed in November 2023 from YC, BoxGroup, and angel investors including founders of Zocdoc, PillPack, and Cityblock Health — providing Medicaid health plans, providers, and state governments with an AI-powered Medicaid navigation platform that pairs AI automation with live human navigators to guide beneficiaries through enrollment, coverage maintenance, and renewal workflows, reducing member churn by 15% and addressing the $50 billion in administrative waste that the US Medicaid system generates annually. Founded in 2023 by Cydney Kim, Nikita Singareddy, and Ben Wesner, Fortuna Health operates with a 12-person team and has been described as "TurboTax for Medicaid."
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.